Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037149 · ClinicalTrials.gov registry record · Phase 1
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Sirnaomics.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 9
- Study locations
NCT05037149: Active Phase 1 study of Solid Tumor, sponsored by Sirnaomics.
NCT05037149 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Sirnaomics. The registered enrollment target is 50 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037149, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Sirnaomics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 9
- Study locations
Study Summary
An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.
Primary Outcome
Recommended starting dose \& schedule
Conditions Studied
Interventions
- DRUG STP707
Study Locations (9)
Arizona
- Mayo Clinic - Phoenix
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Florida
- Mayo Clinic - Jacksonville
Georgia
- Emory University - Atlanta
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health System - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 1 |
What the registry record for NCT05037149 still lists
NCT05037149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which STP707 is the first listed.
NCT05037149 lists 9 locations in 9 states (Arizona, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05037149 about?
NCT05037149 is a clinical study titled "Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors". An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.
What is the current status of trial NCT05037149?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-11-01. Estimated completion is 2024-03-30.
What conditions does trial NCT05037149 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05037149?
The interventions under investigation include: STP707 (DRUG).
Who is sponsoring clinical trial NCT05037149?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037149 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05037149's enrollment target sits among peer trials
50 122nd of 196 higher than 71 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI